In the Spotlight...
There are no spotlights this week
Previous Digests
N17350: a cytotoxic cancer therapy that spares the immune system
November 12, 2025
Cytotoxic cancer treatments, like chemotherapy and radiation, have the potential to synergize with immunotherapies through direct killing of tumor cells, which leads to the release of antigens and damage-associated molecular patterns. However, this potential synergy is often hindered when...
COVID-19 mRNA vaccines provide a surprising boost to ICB therapy efficacy
November 5, 2025
Improving the efficacy of immune checkpoint blockade (ICB) for a larger group of patients, particularly those with immune-cold tumors, is one of the major goals of current immunotherapy research. Based on case reports of patients who had spontaneous tumor...
CRATERs on the tumor cell surface are hubs for antitumor immunity
October 29, 2025
Cancer immunology studies are often performed using mouse models or tumor samples from patients, but these models do not provide ideal opportunities to study immune cells as they interact with endogenous tumors. To visualize tumor–immune interactions in situ, Ludin...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
